EQT VIII to Acquire Majority Interest in Aldevron

EQT VIII has entered into an agreement to acquire a majority interest in Aldevron, a Fargo-based global supplier of plasmid DNA and other biologics, with founders, management and TA Associates retaining minority stakes. EQT will support Aldevron's growth through investments in production capacity, R&D and international expansion as the company continues to serve the gene therapy and broader biopharma markets.